Use the Back button in your browser to see the other results of your search or to select another record.
Extracorporeal shockwave therapy versus platelet rich plasma injection in patients of chronic plantar fasciitis: a randomized controlled trial from a tertiary center of Eastern India |
Pandey S, Kumar N, Kumar A, Biswas A, Sinha U, Pandey J, Ghosh S, Das S, Johnson RA, Kumar R, E VA, Kumari K |
Cureus 2023 Jan;15(1):e34430 |
clinical trial |
7/10 [Eligibility criteria: No; Random allocation: Yes; Concealed allocation: Yes; Baseline comparability: Yes; Blind subjects: No; Blind therapists: No; Blind assessors: Yes; Adequate follow-up: No; Intention-to-treat analysis: Yes; Between-group comparisons: Yes; Point estimates and variability: Yes. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed* |
INTRODUCTION: Plantar fasciitis is a degenerative condition of the plantar fascia that leads to heel and sole pain. Physical modalities, physiotherapy, medication, and orthoses have been tried before as treatments. Extracorporeal shockwave therapy (ESWT) and the injection of autologous platelet-rich plasma (PRP) are generally effective in the treatment of plantar fasciitis, which might be resistant to other conservative measures. The present study compares the efficacy of ESWT and PRP injection in respect of symptomatic relief, functional improvement, and change in plantar fascia thickness (PFT). METHODS: Seventy-two patients were enrolled and randomized into two groups. Patients in the first group received ESWT, whereas patients in the second group received PRP injections. Patients were evaluated using the Visual Analog Scale (VAS) and the American Orthopedic Foot and Ankle Society (AOFAS) score, along with PFT measurement (using ultrasonography) before the treatment and at days 15, 30, and 90 after the treatment. The X2 test was used to compare qualitative variables, and the paired T-test was used to evaluate quantitative data. Quantitative variables had a normal distribution with a standard deviation, and the significance level was set at p-value = 0.05. RESULTS: On day 0, the mean VAS of the ESWT and PRP groups were 6.44 +/- 1.11 and 6.78 +/- 1.17, respectively (p = 0.237). On day 15, the mean VAS of the ESWT and PRP groups were 4.67 +/- 1.45 and 6.67 +/- 1.35, respectively (p < 0.001). At day 30, the mean VAS of the ESWT and PRP groups were 4.97 +/- 1.46 and 4.69 +/- 1.39, respectively (p = 0.391). On day 90, the mean VAS of the ESWT and PRP groups were 5.47 +/- 1.63 and 3.36 +/- 0.96 (p < 0.001). On day 0, the mean PFTs of the ESWT and PRP groups were 4.73 +/- 0.40 and 5.19+/-0.51, respectively (p < 0.001). At day 15, the mean PFT of the ESWT and PRP groups were 4.64 +/- 0.46 and 5.11+/-0.62, respectively (p < 0.001) which changed to 4.52 +/- 0.53 and 4.40 +/- 0.58 at day 30 (p < 0.001), and to 4.40+/-0.50 and 3.82 +/- 0.45 at day 90 (p < 0.001). The mean AOFAS of the ESWT and PRP groups were 68.39 +/- 5.88 and 64.86 +/- 8.95 on day 0 (p = 0.115), 72.58 +/- 6.26 and 67.22 +/- 10.47 on day 15 (p = 0.115), 73.22 +/- 6.92 and 74.72 +/- 7.52 on day 30 (p = 0.276), and 72.75 +/- 7.90 and 81.08 +/- 6.01 on day 90, respectively (p < 0.001). CONCLUSION: Both PRP injection and ESWT are very effective methods to improve pain and cause reduced plantar fascia thickness in patients with chronic plantar fasciitis non-responsive to other conservative measures. PRP injection is more effective at a longer duration as compared to ESWT.
|